Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Carboxymethylcellulose Based Eye Formulation A · 2 trials · 2 indications
The OSDI consists of 12 questions to assess visual function, ocular symptoms and environmental triggers related to dry eye. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4 = all of the time) which is converted to a total score between 0-100. OSDI total scores of 0-12=normal (best), 13-22= mild ocular surface disease, 23-32 =moderate ocular surface disease, and 33-100=severe ocular surface disease (worst). A negative number change from Baseline indicates improvement.
The Ocular Surface Disease Index© Questionnaire is a 12-item survey assessing the overall severity of dry eye disease per patient. Each question is rated on a 5-point scale ranging from 0=none of the time to 4=all of the time for a total possible score of 0=No disease to 100=Maximum severity of disease. A negative change from baseline indicates improvement.
| Arm | Type | Description |
|---|---|---|
| Carboxymethylcellulose Based Eye Drop Formulation A | EXPERIMENTAL | Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days. |
| OPTIVE™ | ACTIVE_COMPARATOR | Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days. |
| Carboxymethylcellulose Based Eye Drop Formulation B | EXPERIMENTAL | Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| Carboxymethylcellulose Preservative-Free Lubricant Eye Drops | ACTIVE_COMPARATOR | Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| Carboxymethylcellulose Based Lubricant Eye Drops | ACTIVE_COMPARATOR | Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days. |
| Name | Type | Description |
|---|---|---|
| Carboxymethylcellulose Based Eye Drop Formulation A | DRUG | Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days. |
| Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops | DRUG | Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days. |
| Carboxymethylcellulose Based Eye Drop Formulation B | DRUG | Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| Carboxymethylcellulose Based Lubricant Eye Drops | DRUG | Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days. |
Inclusion Criteria: * Have used artificial tears for dry eye Exclusion Criteria: * Start date of over the counter, herbal, prescription or nutritional supplements that may affect dry eye or vision within 3 months prior to study start or an anticipated change in dosage during the study * History o...
Top 4 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-319 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Bausch Health Companies Inc. | BHC | 1 | PHASE2 | BL1107 |
Carboxymethylcellulose Based Eye Formulation A is an investigational small molecule eye drop developed by AbbVie Inc. (ABBV) for dry eye disease and dry eye syndromes. It is designed as a topical ophthalmic formulation and has been studied in Phase 3 clinical trials. It is not yet approved for marketing.
Carboxymethylcellulose Based Eye Formulation A is being developed for the treatment of dry eye disease and dry eye syndromes. These conditions involve insufficient tear production or poor tear quality, leading to ocular discomfort and surface damage. The formulation is intended for topical administration to the eye.
Carboxymethylcellulose Based Eye Formulation A is developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker symbol ABBV. AbbVie is the sponsor responsible for the clinical development of this ophthalmic formulation.
Carboxymethylcellulose Based Eye Formulation A is in Phase 3 clinical development. Two Phase 3 trials have been completed, and no active trials are currently recruiting. The drug remains investigational and has not been approved by the FDA for any indication.
Carboxymethylcellulose Based Eye Formulation A has been evaluated in two completed Phase 3 trials. NCT01664949 compared the eye drop formulation with OPTIVE in 460 subjects with dry eye disease across multiple countries. NCT01459588 assessed safety, efficacy, and acceptability in 315 subjects with dry eye syndromes in the United States.
Yes, Carboxymethylcellulose Based Eye Formulation A is also known as Carboxymethylcellulose Based Eye Drop Formulation A. Both names refer to the same investigational ophthalmic product developed by AbbVie Inc. for dry eye disease and dry eye syndromes.